Trending today
Load more
Login / Create account for advanced features
Generating your feed, please be patient ...
Latest news
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial - PubMed | Zootzle